A case of dupilumab combination therapy for exacerbation of atopic dermatitis in a patient with eosinophilic granulomatosis with polyangiitis treated with mepolizumab

Mod Rheumatol Case Rep. 2023 Dec 29;8(1):159-162. doi: 10.1093/mrcr/rxad059.

Abstract

We report a 60-year-old male with eosinophilic granulomatosis with polyangiitis (EGPA) complicated with atopic dermatitis (AD). The patient was initially treated with prednisolone, cyclosporine A, and mepolizumab (MEPO). Due to worsening skin symptoms after prednisolone tapering, dupilumab (DUP) was added as an adjunctive therapy for AD confirmed by skin biopsy. The combination therapy of MEPO and DUP resulted in rapid improvement of skin symptoms, suggesting it may be an effective therapeutic option for patients with EGPA and AD. This case report emphasises the importance of a multidisciplinary approach in treating complex diseases such as EGPA and AD.

Keywords: Eosinophilic granulomatosis with polyangiitis (EGPA); atopic dermatitis (AD); dupilumab; mepolizumab.

Publication types

  • Case Reports

MeSH terms

  • Churg-Strauss Syndrome* / diagnosis
  • Dermatitis, Atopic* / complications
  • Dermatitis, Atopic* / diagnosis
  • Dermatitis, Atopic* / drug therapy
  • Granulomatosis with Polyangiitis* / complications
  • Granulomatosis with Polyangiitis* / diagnosis
  • Granulomatosis with Polyangiitis* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Prednisolone / therapeutic use

Substances

  • dupilumab
  • mepolizumab
  • Prednisolone